282 related articles for article (PubMed ID: 25783795)
21. Epidemiology of chronic myeloid leukaemia (CML).
Rohrbacher M; Hasford J
Best Pract Res Clin Haematol; 2009 Sep; 22(3):295-302. PubMed ID: 19959081
[TBL] [Abstract][Full Text] [Related]
22. Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
Gunnarsson N; Sandin F; Höglund M; Stenke L; Björkholm M; Lambe M; Olsson-Strömberg U; Richter J; Själander A
Eur J Haematol; 2016 Oct; 97(4):387-92. PubMed ID: 26833713
[TBL] [Abstract][Full Text] [Related]
23. Epidemiology of chronic myeloid leukaemia: an update.
Höglund M; Sandin F; Simonsson B
Ann Hematol; 2015 Apr; 94 Suppl 2():S241-7. PubMed ID: 25814090
[TBL] [Abstract][Full Text] [Related]
24. Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
Hu B; Savani BN
Eur J Haematol; 2014 Sep; 93(3):179-86. PubMed ID: 24766312
[TBL] [Abstract][Full Text] [Related]
25. EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib.
Tao Z; Liu B; Zhao Y; Wang Y; Zhang R; Han M; Zhang L; Li C; Ru K; Mi Y; Wang J
Leuk Res; 2014 Sep; 38(9):1030-5. PubMed ID: 24996976
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
27. Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study.
Lauseker M; Gerlach R; Tauscher M; Hasford J
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1441-7. PubMed ID: 27085527
[TBL] [Abstract][Full Text] [Related]
28. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
[TBL] [Abstract][Full Text] [Related]
29. Recent improvement in completeness of incidence data on acute myeloid leukemia in US cancer registries.
Polednak AP
J Registry Manag; 2014; 41(2):77-84. PubMed ID: 25153013
[TBL] [Abstract][Full Text] [Related]
30. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
Gunnarsson N; Stenke L; Höglund M; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Richter J; Wadenvik H; Wallvik J; Själander A
Br J Haematol; 2015 Jun; 169(5):683-8. PubMed ID: 25817799
[TBL] [Abstract][Full Text] [Related]
31. Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century.
Pulte D; Redaniel MT; Bird J; Jeffreys M
Eur J Haematol; 2015 Jun; 94(6):540-5. PubMed ID: 25315799
[TBL] [Abstract][Full Text] [Related]
32. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany.
Rohrbacher M; Berger U; Hochhaus A; Metzgeroth G; Adam K; Lahaye T; Saussele S; Müller MC; Hasford J; Heimpel H; Hehlmann R
Leukemia; 2009 Mar; 23(3):602-4. PubMed ID: 18784744
[No Abstract] [Full Text] [Related]
33. Incidence of chronic myeloid leukemia in Calgary, Alberta, Canada.
Nguyen LT; Guo M; Naugler C; Rashid-Kolvear F
BMC Res Notes; 2018 Nov; 11(1):780. PubMed ID: 30382890
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
35. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
Hoffmann VS; Baccarani M; Lindoerfer D; Castagnetti F; Turkina A; Zaritsky A; Hellmann A; Prejzner W; Steegmann JL; Mayer J; Indrak K; Colita A; Rosti G; Pfirrmann M
Leukemia; 2013 Oct; 27(10):2016-22. PubMed ID: 23752173
[TBL] [Abstract][Full Text] [Related]
36. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Tauchi T; Kizaki M; Okamoto S; Tanaka H; Tanimoto M; Inokuchi K; Murayama T; Saburi Y; Hino M; Tsudo M; Shimomura T; Isobe Y; Oshimi K; Dan K; Ohyashiki K; Ikeda Y;
Leuk Res; 2011 May; 35(5):585-90. PubMed ID: 21145591
[TBL] [Abstract][Full Text] [Related]
37. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
[TBL] [Abstract][Full Text] [Related]
38. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.
Mohammadi M; Cao Y; Glimelius I; Bottai M; Eloranta S; Smedby KE
BMC Cancer; 2015 Nov; 15():850. PubMed ID: 26537111
[TBL] [Abstract][Full Text] [Related]
39. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
40. Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries.
Silberman G; Crosse MG; Peterson EA; Weston RC; Horowitz MM; Appelbaum FR; Cheson BD
N Engl J Med; 1994 Oct; 331(16):1063-7. PubMed ID: 8090167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
